Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide.

Johann S de BonoMark T FlemingJudy S WangRichard CathomasManuel Selvi MirallesJohn BothosMary Jane HinrichsQu ZhangPeng HeMarna WilliamsAnton I RosenbaumMeina LiangKapil VashishtSong ChoPablo MartinezDaniel P Petrylak

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Following dose escalation, no MTD was identified. Clinical responses occurred at higher doses, but were not durable as patients had to discontinue treatment due to TRAEs.

Keyphrases

prostate cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
cancer therapy
prognostic factors
clinical trial
randomized controlled trial
open label
patient reported outcomes
patient reported